Hospital Readmissions in Left Ventricular Assist Device (LVAD) Recipients: Analysis of Bridge to Transplant (BTT) and Destination Therapy (DT)

Bradner, Michael W.; Whitson, Bryan A.; Eckman, Peter; Lacey, Alexandra; Colvin-Adams, Monica; Liao, Kuo‐Wei

doi:10.1016/j.healun.2013.01.1015

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The readmission frequency differed between implanted HeartMate-II or HeartWare devise (Haglund et al, 2015) but was not different between destination therapy and bridge to transplantation LVAD recipients (Bradner et al, 2013). Based on several studies (Bradner et al, 2013; Haglund et al, 2015; Joy et al, 2016), we considered gastrointestinal bleeding to be a risk factor for the increased readmission rate in this study, and this risk factor was associated with older age in patients enrolled in this study.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of inpatient cardiac rehabilitation for patients with treated left ventricular assist device in Korea: 1-year follow-up

Seo

Park

et al. 2019

J Exerc Rehabil

View full text Add to dashboard Cite

In Korea, the first patient with a left ventricular assist device (LVAD) for destination therapy had successful implantation of a continuous-flow model in 2012. We investigated the safety and efficacy of exercise therapy with LVAD implantation 15 Korean patients. We retrospectively reviewed 15 patients (mean age, 67.4±11.6 years; 10 males, 5 female, left ventricular ejection fraction 23.6%±7.1%), including 4 with implanted continuous-flow and 11 an axial-flow LVAD. The New York Heart Association functional classification, ejection fraction, and quality of life were obtained. Survival rate, adverse events, admission rates, and enrollment rates in cardiac rehabilitation were investigated. Survival at 6 and 12 months was 100% and 89%, respectively. The New York Heart Association functional classification improved from 3.4±0.5 to 2.3±0.05 at 12 months postoperatively ( P <0.0001). The ejection fraction significantly increased from 23.6%±7.2% on the preoperative day to 35.4%±14.2% at 1 year ( P <0.0018). The quality of life was also improved at 1 year ( P <0.0001). The most common adverse events were bleeding (56%) and dyspnea (44%). The number of admissions was 3.2 per patient-year. LVAD therapy is a safe and effective treatment option with exercise intervention for Korean patients waiting for heart transplantation or those who were ineligible for heart transplantation. A larger study with longer follow-up is needed to determine details clinical outcomes after LVAD.

show abstract